Placebo for Abemaciclib
Phase 3
Eli LillyPlacebo for Abemaciclib is one of 27 therapeutic programs targeting Prostatic Neoplasms. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
31 competitors in Prostatic Neoplasms
#DrugCompanyPhaseTrials
1Erleada
Johnson & JohnsonPhase 3
Zytiga
Johnson & JohnsonPhase 3
Verzenio
Eli LillyPhase 3
Xtandi
AstellasPhase 3
Keytruda
Merck & Co.Phase 3
Rayos
RRoxane Laboratories
Phase 3
Casodex
IIstituto Clinico Humanitas
Phase 3
Androgen Deprivation Therapy
Johnson & JohnsonPhase 3
Prednisone or Prednisolone
Johnson & JohnsonPhase 3
Gnrh
MMassachusetts General Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Placebo for Abemaciclib. EMBL-EBI & Wellcome Sanger Institute.
- [3]